Segment Information

3 Months Ended

Mar. 31, 2016

Segment Information

Segment Information

Note 7. Segment Information

The Company operates in one business segment, which primarily focuses on the development and global commercialization of genomic based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. As of March 31, 2016, the majority of the Company’s product revenues have been derived from sales of one product, the Oncotype DX breast cancer test.

The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location.

	Three Months Ended
	March 31,
	2016		2015
	(In thousands)
United States	$	70,495	$	57,717
Outside of the United States		10,399		10,435
Total revenues	$	80,894	$	68,152